BR112012011316A2 - tivozanib e temsirolimus em combinação - Google Patents

tivozanib e temsirolimus em combinação

Info

Publication number
BR112012011316A2
BR112012011316A2 BR112012011316A BR112012011316A BR112012011316A2 BR 112012011316 A2 BR112012011316 A2 BR 112012011316A2 BR 112012011316 A BR112012011316 A BR 112012011316A BR 112012011316 A BR112012011316 A BR 112012011316A BR 112012011316 A2 BR112012011316 A2 BR 112012011316A2
Authority
BR
Brazil
Prior art keywords
tivozanib
temsirolimus
combination
dose
per day
Prior art date
Application number
BR112012011316A
Other languages
English (en)
Inventor
John L Ryan
Pankaj Bhargava
W Brooke Esteves
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Publication of BR112012011316A2 publication Critical patent/BR112012011316A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

patente de invenção: tivozanib e temsirolimus em combinação. a presente invenção refere-se a um método de tratamento de um tumor em um paciente humano. o método compreende coadministração ao paciente de: (a) uma dose de 1,5 mg de tivozanib por dia, e (b) uma dose de 25 mg de temsirolimus por semana. em algumas modalidades da invenção, o tivozanib é administrado em uma progranação de repetição de uma dose por dia durante três semana, seguindo de uma semana sem administração de tivozanib. o métdod descrito é particularme adequedo para os tratamento do carcinoma de células renais.
BR112012011316A 2009-11-13 2010-11-11 tivozanib e temsirolimus em combinação BR112012011316A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26125209P 2009-11-13 2009-11-13
US12/856,414 US7998973B2 (en) 2009-11-13 2010-08-13 Tivozanib and temsirolimus in combination
PCT/US2010/056372 WO2011060162A1 (en) 2009-11-13 2010-11-11 Tivozanib and temsirolimus in combination

Publications (1)

Publication Number Publication Date
BR112012011316A2 true BR112012011316A2 (pt) 2015-10-06

Family

ID=43992030

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011316A BR112012011316A2 (pt) 2009-11-13 2010-11-11 tivozanib e temsirolimus em combinação

Country Status (10)

Country Link
US (1) US7998973B2 (pt)
EP (1) EP2498606A4 (pt)
JP (1) JP2013510866A (pt)
KR (1) KR20120104574A (pt)
CN (1) CN102781238A (pt)
BR (1) BR112012011316A2 (pt)
CA (1) CA2780495A1 (pt)
MX (1) MX2012005497A (pt)
RU (1) RU2012123970A (pt)
WO (1) WO2011060162A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642918B2 (en) * 2011-12-16 2017-05-09 Pfizer Inc. Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
CA2863188A1 (en) 2012-02-02 2013-08-08 Acceleron Pharma Inc. Alk1 antagonists and their uses in treating renal cell carcinoma
EA202191273A1 (ru) 2018-11-05 2021-09-15 Авео Фармасьютикалз, Инк. Применение тивозаниба для лечения субъектов с рефрактерным раком

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100879669B1 (ko) * 2001-04-27 2009-01-21 기린 파마 가부시끼가이샤 아졸릴기를 갖는 퀴놀린 유도체 및 퀴나졸린 유도체
WO2004004644A2 (en) * 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
EP1559715B1 (en) * 2002-10-21 2007-09-26 Kirin Beer Kabushiki Kaisha N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form
TW200803842A (en) * 2005-11-04 2008-01-16 Wyeth Corp Antineoplastic combinations of temsirolimus and sunitinib malate

Also Published As

Publication number Publication date
WO2011060162A1 (en) 2011-05-19
EP2498606A1 (en) 2012-09-19
CA2780495A1 (en) 2011-05-19
US20110118297A1 (en) 2011-05-19
EP2498606A4 (en) 2013-05-15
KR20120104574A (ko) 2012-09-21
CN102781238A (zh) 2012-11-14
MX2012005497A (es) 2012-07-03
US7998973B2 (en) 2011-08-16
RU2012123970A (ru) 2013-12-20
JP2013510866A (ja) 2013-03-28

Similar Documents

Publication Publication Date Title
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
CY1116727T1 (el) Θεραπεια πολλαπλης σκληρυνσης me laquinimod
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
NZ714963A (en) Compositions and methods for treating anemia
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MY173215A (en) Acetylcysteine compositions and methods of use thereof
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
BR112013007423A2 (pt) terapia combinada no que diz respeito ao tratamento da infecção por hcv
MX2013003523A (es) Composicion farmaceutica de dosis baja.
BR112012011316A2 (pt) tivozanib e temsirolimus em combinação
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
NZ597675A (en) Medicament for the long term nsaid use
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
UA45323U (ru) Способ коррекции дислипидемии у больных подагрой
UA57208U (ru) Способ лечения гнойно-воспалительных заболеваний мягких тканей челюстно-лицевой области и шеи
CY1117605T1 (el) Θεραπεια της ασθενειας crohn me laquinimod

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.